JP2012502909A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502909A5
JP2012502909A5 JP2011526923A JP2011526923A JP2012502909A5 JP 2012502909 A5 JP2012502909 A5 JP 2012502909A5 JP 2011526923 A JP2011526923 A JP 2011526923A JP 2011526923 A JP2011526923 A JP 2011526923A JP 2012502909 A5 JP2012502909 A5 JP 2012502909A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cluster headache
pharmaceutically acceptable
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011526923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502909A (ja
JP5690732B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/055971 external-priority patent/WO2010033392A2/en
Publication of JP2012502909A publication Critical patent/JP2012502909A/ja
Publication of JP2012502909A5 publication Critical patent/JP2012502909A5/ja
Application granted granted Critical
Publication of JP5690732B2 publication Critical patent/JP5690732B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011526923A 2008-09-17 2009-09-04 群発頭痛障害を治療するための方法及びキット Active JP5690732B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9777308P 2008-09-17 2008-09-17
US61/097,773 2008-09-17
PCT/US2009/055971 WO2010033392A2 (en) 2008-09-17 2009-09-04 Methods and kits for treating cluster headache disorders

Publications (3)

Publication Number Publication Date
JP2012502909A JP2012502909A (ja) 2012-02-02
JP2012502909A5 true JP2012502909A5 (enExample) 2012-10-04
JP5690732B2 JP5690732B2 (ja) 2015-03-25

Family

ID=42040074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526923A Active JP5690732B2 (ja) 2008-09-17 2009-09-04 群発頭痛障害を治療するための方法及びキット

Country Status (10)

Country Link
US (2) US8415371B2 (enExample)
EP (1) EP2331100B1 (enExample)
JP (1) JP5690732B2 (enExample)
CN (1) CN102164603B (enExample)
BR (1) BRPI0918623A2 (enExample)
CA (1) CA2737135C (enExample)
GB (1) GB2475660B (enExample)
IL (1) IL211714A (enExample)
MX (1) MX2011002883A (enExample)
WO (1) WO2010033392A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859579B2 (en) * 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
EP2331100B1 (en) * 2008-09-17 2014-07-16 The McLean Hospital Corporation Methods and kits for treating cluster headache disorders
EP3934633A4 (en) * 2019-03-07 2023-03-29 Arbormentis LLC COMPOSITIONS AND METHODS OF USE INCLUDING SUBSTANCES HAVING NEURAL PLASTICITY ACTIONS ADMINISTERED IN NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSES AND FORMULATIONS
EP4125877A4 (en) * 2020-03-25 2024-05-01 Ceruvia Lifesciences LLC 2-BROMO-LYSERGIC ACID DIETHYLAMIDE FOR PSYCHOACTIVE SUBSTANCE ABUSE
CA3205858A1 (en) * 2020-12-22 2022-06-30 Betterlife Pharma Inc. Methods of treating mental or mood disorders using 2-bromo-lsd
US20240180894A1 (en) * 2021-03-22 2024-06-06 Betterlife Pharma Inc. Methods of treating mental and/or mood disorders using 2-bromo-lsd alone or in combination with a mtor inhibitor
EP4387623A4 (en) * 2021-08-19 2025-07-02 Mind Medicine Inc ORODISPERSIBLE LYOPHILIZED TABLET FORMULATIONS OF D-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
MX2024003472A (es) 2021-09-20 2024-06-12 Blife Therapeutics Inc Derivados del lsd, sintesis y metodo para el tratamiento de enfermedades y trastornos.
EP4630418A1 (en) 2022-12-31 2025-10-15 Ceruvia Lifesciences LLC Salts of 2-bromolysergic acid diethylamide
WO2024145604A2 (en) 2022-12-31 2024-07-04 Ceruvia Lifesciences Llc Process for synthesizing 2-bromolysergic acid diethylamide via controlled hydrolysis of bromocriptine
WO2024145546A1 (en) 2022-12-31 2024-07-04 Ceruvia Lifesciences Llc Process for synthesizing 2-bromolysergic acid diethylamide via controlled bromination of lysergic acid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3228959A (en) * 1962-01-16 1966-01-11 Geigy Chem Corp Quaternary salts of certain indolealkylamines and therapeutic uses thereof
US4524072A (en) * 1984-06-18 1985-06-18 Zivin Justin A Reduction of stroke damage
GB8618700D0 (en) * 1986-07-31 1986-09-10 Beecham Group Plc Compounds
EP0255297B1 (en) * 1986-07-31 1993-04-21 Beecham Group Plc Azabicyclic compounds, process for their preparation, and their pharmaceutical use
US20030225002A1 (en) * 2002-02-26 2003-12-04 Livingstone Ian R. Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
EP2331100B1 (en) * 2008-09-17 2014-07-16 The McLean Hospital Corporation Methods and kits for treating cluster headache disorders

Similar Documents

Publication Publication Date Title
JP2012502909A5 (enExample)
JP2013505205A5 (enExample)
JP2016518387A5 (enExample)
JP2018193377A5 (enExample)
JP2012520866A5 (enExample)
WO2012079092A3 (en) Testosterone undecanoate compositions
JP2015515475A5 (enExample)
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
JP2012193216A5 (enExample)
WO2007081975A3 (en) Method of treating multiple sclerosis
JP2010525050A5 (enExample)
MX2010005676A (es) Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida.
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
JP2016540738A5 (enExample)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
FI4321157T3 (fi) Angiotensiinireseptorin salpaajan (arb) ja neutraalin endopeptidaasin estäjän (nepi) yhdistelmän uusi käyttötapa
JP2010522137A5 (enExample)
JP2012502047A5 (enExample)
RU2010142456A (ru) Синергические комбинации 5'-метилтиоаденозина
JP2013541583A5 (enExample)
JP2016530291A5 (enExample)
JP2011511006A5 (ja) 肺病態に対する医薬組成物
IL278188B2 (en) Sublingual formulation of riluzole
JP2016512817A5 (enExample)
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina